Liver Disease Newco Alentis Raises CHF12.5m Series A

 
• By Mike Ward

A syndicate of European VCs commits CHF12.5m to Alentis Therapeutics a Swiss-French start-up with a discovery platform focusing on liver diseases. Lead program is a humanized monoclonal antibody targeting liver fibrosis and hepatocellular carcinoma.

Liver cancer, CT scan upper abdomen.
Advanced liver disease and cancer are major clinical challenges

More from Alimentary/Metabolic

More from Therapy Areas